芪参益气滴丸联合替格瑞洛对冠心病患者血浆内脂素水平和血清氧化应激标志物的影响
|
摘要
目的研究芪参益气滴丸联合替格瑞洛对冠心病患者血浆内脂素水平和血清氧化应激标志物的影响。方法选择2015年1月—2017年1月西宁市第一人民医院收治的120例冠心病患者,随机分为两组。对照组口服替格瑞洛治疗,观察组联合服用芪参益气滴丸。两组均治疗4周。比较两组治疗前后的血浆内脂素水平和血清氧化应激水平的改变情况。结果观察组的有效率明显高于对照组,差异有统计学意义(P<0.05)。治疗后,两组的超氧化物歧化酶(SOD)、晚期糖基化终末产物(AGEs)、丙二醛(MDA)以及晚期蛋白质氧化产物(AOPP)等氧化应激指标均明显改善,同组治疗前后比较差异有统计学意义(P<0.05);且观察组明显优于对照组,组间差异有统计学意义(P<0.05)。治疗后,两组的血浆内脏脂肪素(visfatin)水平均明显降低,同组治疗前后比较差异有统计学意义(P<0.05);且观察组明显低于对照组,差异有统计学意义(P<0.05)。观察组1年后发生心肌梗死2例,心力衰竭1例,心绞痛2例,消化道出血3例,冠脉支架再狭窄1例,再次血运重建2例,总发生率为18.33%,明显低于对照组的31.67%,差异有统计学意义(P<0.05)。结论芪参益气滴丸联合替格瑞洛对冠心病患者的治疗效果明显优于单用西药替格瑞洛,不仅能有效改善患者的血浆内脂素水平和氧化应激状态,还有助于改善预后情况。
Objective To study the effect of Qishen Yiqi Dripping Pills combined with Ticagrelor on plasma visfatin level and serum oxidative stress markers in patients with coronary heart disease. Methods A total of 120 cases of patients with coronary heart disease who were treated in our hospital from January 2015 to January 2017, were divided into two groups randomly. The control group was treated with the oral administration of Ticagrelor and the observation group was given Qishen Yiqi Dripping Pills. Plasma visfatin levels and serum oxidative stress levels were compared between the two groups before and after treatment. Results The effective rate of the observation group was significantly higher than control group(P < 0.05). After treatment, the oxidative stress indexes of SOD, AGEs, MDA and AOPP in the two groups were significantly improved(P < 0.05), and the observation group was significantly better than the control group(P < 0.05). The plasma visfatin levels of the two groups were significantly lower(P < 0.05), and the observation group was lower(P < 0.05). The total incidence of myocardial infarction, heart failure, angina, gastrointestinal bleeding,coronary stent restenosis and re revascularization after 1 years in the observation group was significantly lower than control group(P < 0.05). Conclusion The effect of Qishen Yiqi Dropping Pills combined with Ticagrelor on patients with coronary heart disease is obviously better. It can not only improve the plasma lipoprotein level and oxidative stress state of the patients, but also improve the prognosis.
Objective To study the effect of Qishen Yiqi Dripping Pills combined with Ticagrelor on plasma visfatin level and serum oxidative stress markers in patients with coronary heart disease. Methods A total of 120 cases of patients with coronary heart disease who were treated in our hospital from January 2015 to January 2017, were divided into two groups randomly. The control group was treated with the oral administration of Ticagrelor and the observation group was given Qishen Yiqi Dripping Pills. Plasma visfatin levels and serum oxidative stress levels were compared between the two groups before and after treatment. Results The effective rate of the observation group was significantly higher than control group(P < 0.05). After treatment, the oxidative stress indexes of SOD, AGEs, MDA and AOPP in the two groups were significantly improved(P < 0.05), and the observation group was significantly better than the control group(P < 0.05). The plasma visfatin levels of the two groups were significantly lower(P < 0.05), and the observation group was lower(P < 0.05). The total incidence of myocardial infarction, heart failure, angina, gastrointestinal bleeding,coronary stent restenosis and re revascularization after 1 years in the observation group was significantly lower than control group(P < 0.05). Conclusion The effect of Qishen Yiqi Dropping Pills combined with Ticagrelor on patients with coronary heart disease is obviously better. It can not only improve the plasma lipoprotein level and oxidative stress state of the patients, but also improve the prognosis.
引文
[1] Zhao H, Chen J, Shi Q, et al. Metabolomics-based study of clinical and animal plasma samples in coronary heart disease with blood stasis syndrome[J]. Evid Based Complement Alternat Med, 2017, 2012(1):638723.
[2]孙卉丽,王硕仁,王亚红.八段锦应用于冠心病心脏康复的系统评价[J].长春中医药大学学报, 2016, 32(2):326-329.
[3]田野,顾健霞.芪参益气滴丸治疗冠心病心力衰竭的Meta分析[J].中国中医急症, 2016, 25(9):1725-1727.
[4]胡盛寿,黄方炯.冠心病外科治疗学[M].北京:科学出版社, 2003:15-23.
[5] Campo G, Vieceli D S F, Pavasini R, et al. Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease[J]. Thromb Haemost, 2017, 117(06):1208-1216.
[6]苗灵娟,杨永枝,邢海燕,等.炙甘草汤联合胺碘酮治疗气阴两虚冠心病室性心律失常疗效观察[J].陕西中医,2017, 38(2):169-170.
[7]陈雪明,陈健.芪参益气滴丸对冠心病患者血液黏稠度及血管内皮功能的影响[J].医学综述, 2016, 22(19):3896-3898.
[8]黄述华.芪参益气滴丸在社区冠心病2级预防中的应用[J].吉林中医药, 2016, 36(7):682-685.
[9]景强强,姚龙.芪参益气滴丸对PCI术后近期炎症因子的影响[J].湖北中医药大学学报, 2016, 18(5):38-40.
[10]李佩,刘鹏,张鹏,等.芪参益气滴丸联合曲美他嗪治疗慢性心力衰竭患者疗效观察及对其心肌和血脂的影响研究[J].世界中医药, 2017, 12(8):1812-1815.
[11]薛玉刚,王翅遥,尚福军,等.芪参益气滴丸联合薯蓣皂苷片治疗冠心病心绞痛的临床研究[J].现代药物与临床, 2017, 32(10):1832-1835.
[12]赵翠萍,姜丽丝,曹滢,等.芪参益气滴丸治疗老年冠心病的临床研究[J].中医药学报, 2012, 40(4):113-114.
[13]彭红玉,郑绪伟,柳景华,等.血清内脂素水平与慢性稳定性冠心病的关系[J].中国动脉硬化杂志, 2016, 24(1):67-71.
[14]王爽,郑秀艳,孙文华,等.阿托伐他汀联合依折麦布对冠心病患者氧化应激及血脂水平的影响[J].现代生物医学进展, 2017, 17(13):2470-2473.
[15]赵佳,左林,姚创利,等.冠心病患者血清同型半胱氨酸水平与氧化应激的关系研究[J].现代检验医学杂志,2016, 31(5):27-29.
[16]姚志灵,陈亮,王志胜,等.老年冠心病病人不同糖代谢状态与氧化应激水平的相关性研究[J].中西医结合心脑血管病杂志, 2016, 14(19):2273-2275.
[2]孙卉丽,王硕仁,王亚红.八段锦应用于冠心病心脏康复的系统评价[J].长春中医药大学学报, 2016, 32(2):326-329.
[3]田野,顾健霞.芪参益气滴丸治疗冠心病心力衰竭的Meta分析[J].中国中医急症, 2016, 25(9):1725-1727.
[4]胡盛寿,黄方炯.冠心病外科治疗学[M].北京:科学出版社, 2003:15-23.
[5] Campo G, Vieceli D S F, Pavasini R, et al. Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease[J]. Thromb Haemost, 2017, 117(06):1208-1216.
[6]苗灵娟,杨永枝,邢海燕,等.炙甘草汤联合胺碘酮治疗气阴两虚冠心病室性心律失常疗效观察[J].陕西中医,2017, 38(2):169-170.
[7]陈雪明,陈健.芪参益气滴丸对冠心病患者血液黏稠度及血管内皮功能的影响[J].医学综述, 2016, 22(19):3896-3898.
[8]黄述华.芪参益气滴丸在社区冠心病2级预防中的应用[J].吉林中医药, 2016, 36(7):682-685.
[9]景强强,姚龙.芪参益气滴丸对PCI术后近期炎症因子的影响[J].湖北中医药大学学报, 2016, 18(5):38-40.
[10]李佩,刘鹏,张鹏,等.芪参益气滴丸联合曲美他嗪治疗慢性心力衰竭患者疗效观察及对其心肌和血脂的影响研究[J].世界中医药, 2017, 12(8):1812-1815.
[11]薛玉刚,王翅遥,尚福军,等.芪参益气滴丸联合薯蓣皂苷片治疗冠心病心绞痛的临床研究[J].现代药物与临床, 2017, 32(10):1832-1835.
[12]赵翠萍,姜丽丝,曹滢,等.芪参益气滴丸治疗老年冠心病的临床研究[J].中医药学报, 2012, 40(4):113-114.
[13]彭红玉,郑绪伟,柳景华,等.血清内脂素水平与慢性稳定性冠心病的关系[J].中国动脉硬化杂志, 2016, 24(1):67-71.
[14]王爽,郑秀艳,孙文华,等.阿托伐他汀联合依折麦布对冠心病患者氧化应激及血脂水平的影响[J].现代生物医学进展, 2017, 17(13):2470-2473.
[15]赵佳,左林,姚创利,等.冠心病患者血清同型半胱氨酸水平与氧化应激的关系研究[J].现代检验医学杂志,2016, 31(5):27-29.
[16]姚志灵,陈亮,王志胜,等.老年冠心病病人不同糖代谢状态与氧化应激水平的相关性研究[J].中西医结合心脑血管病杂志, 2016, 14(19):2273-2275.